Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Free Cash Flow: 2020-2025

Historic Free Cash Flow for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Sep 2025 value amounting to $16.3 million.

  • Tarsus Pharmaceuticals' Free Cash Flow rose 282.98% to $16.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$57.5 million, marking a year-over-year increase of 43.41%. This contributed to the annual value of -$84.6 million for FY2024, which is 28.91% up from last year.
  • Latest data reveals that Tarsus Pharmaceuticals reported Free Cash Flow of $16.3 million as of Q3 2025, which was up 153.79% from -$30.4 million recorded in Q2 2025.
  • Over the past 5 years, Tarsus Pharmaceuticals' Free Cash Flow peaked at $20.5 million during Q2 2021, and registered a low of -$39.3 million during Q4 2023.
  • Moreover, its 3-year median value for Free Cash Flow was -$22.3 million (2023), whereas its average is -$21.7 million.
  • The largest annual percentage gain for Tarsus Pharmaceuticals' Free Cash Flow in the last 5 years was 810.06% (2021), contrasted with its biggest fall of 489.03% (2021).
  • Tarsus Pharmaceuticals' Free Cash Flow (Quarterly) stood at -$12.4 million in 2021, then climbed by 11.25% to -$11.0 million in 2022, then plummeted by 257.56% to -$39.3 million in 2023, then soared by 43.42% to -$22.3 million in 2024, then soared by 282.98% to $16.3 million in 2025.
  • Its Free Cash Flow stands at $16.3 million for Q3 2025, versus -$30.4 million for Q2 2025 and -$21.2 million for Q1 2025.